Oncogenic K-ras “addiction” and synthetic lethality
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Mutational activation of the K-ras gene is a frequent oncogenic event in human cancers, associated with poor clinical prognosis and resistance to treatment.Despite efforts to develop therapeutics that target K-ras or its downstream effector molecules, clinical benefit in this setting has not yet been achieved.An alternative approach to K-ras mutant cancers involves the identification of genes that selectively drive the maintenance of tumors that are "addicted" to or dependent on mutant K-ras.Disruption of these genes would result in "synthetic lethality" specifically in cancer cells driven by mutant K-ras, thereby potentially sparing non-tumor cells.Through this approach, three recent reports have identified PLK1, STK33, SYK, RON and integrin β6 as previously unappreciated pharmacologically tractable targets in the setting of K-ras activation, which drive growth and survival selectively in K-ras-dependent cancer cells.K-ras mutations are among the most frequent oncogenic events in human cancers, most often seen in adenocarcinomas of the lung, pancreas and colon, 1 and K-ras mutant cancers are notoriously refractory to available therapies.K-ras is a small GTPase with binary molecular switch functionality, which upon activation engages effectors such as the Raf and PI3 kinases, thereby stimulating signaling cascades 2 that can impact proliferation, apoptosis and differentiation. 3K-ras mutational activation in mouse models of tumorigenesis drives neoplastic and malignant progression. 4Thus, mutational activation of K-ras is a well established tumor-initiating event, underscored by the observation that K-ras mutations arise in early pre-neoplastic lesions. 5,6 However, it is unclear whether K-ras activity is required for tumor maintenance during later stages of malignant progression.Transgenic mouse models of Myc-or Ras-induced oncogenesis, in which these
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Self-citation
Cited by
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
EMT as the ultimate survival mechanism of cancer cells
Tiwari, N., Gheldof, A., Tatari, M., & Christofori, G. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.013 · Cited by 512
Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Marcotte, R., Brown, K. R., Suarez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P. M., Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J. L. Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0224 · Cited by 303
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Self-citationCell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3872 · Cited by 106
KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
Shukla, S., Allam, U. S., Ahsan, A., Chen, G., Krishnamurthy, P. M., Marsh, K., Rumschlag, M., Shankar, S., Whitehead, C., Schipper, M., et al. (2014) · Neoplasia · doi:10.1593/neo.14184 · Cited by 96
Metadata
- Authors
- Singh, A., & Settleman, J.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 8
- Issue
- 17
- Pages
- 2676-2678
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2020201038
- Cited by
- 44
- References
- 2
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.